Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Prime Medicine, Inc. (PRME – Research Report), ...
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback